4th Quarter - Report

MEDIMMUNE, LLC. for MEDIMMUNE LLC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$370,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 19, 2012 $370,000 Replaced
4th Quarter - Amendment Apr 19, 2012 $580,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 2055/Pub. L. No. 112-74 - Consolidated Appropriations Act, 2012, provisions relating to funding for Health and Human Services Issues related to CDC Burden of Disease Study on Respiratory Syncytial Virus (RSV), including RSV prophylaxis; vaccine and related services reimbursement; Medicaid reimbursement; health reform implementation; biologics data exclusivity; and, debt and deficit reduction proposals on Medicaid federal funding, Medicaid rebates, and Medicare Part D rebates

Foreign entity interest: As the ultimate parent of MedImmune, LLC, AstraZeneca PLC has interests in the issues lobbied.

LobbyistCovered position, as disclosed
LAUREN RANDALL BUCKLEY —
VANESSA PROCTER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2055 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.